EMEA-003034-PIP01-21
Key facts
| Active substance |
Senaparib
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0445/2021
|
| PIP number |
EMEA-003034-PIP01-21
|
| Pharmaceutical form(s) |
Capsule, hard
|
| Condition(s) / indication(s) |
Treatment of metastatic castrate-resistant prostate cancer
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
IMPACT Therapeutics US, Inc.
Email: regulatoryaffairs@impacttherapeutics.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|